Piotr Czempik: Anti-Xa-Guided Enoxaparin Prophylaxis in Extreme Obesity
Piotr Czempik, Chair of Department of Anesthesiology and Intensive Care at Medical University of Silesia, shared on LinkedIn about recent article he and his colleague co-authored, published in Journal of Transfusion Medicine and Hemostasis, adding:
”How to provide safe and effective antithrombotic prophylaxis in extremely obese patients?
Happy to share our latest case report addressing this challenging critical care issue.
What the paper covers:
Patients >150–200 kg often fail to reach target anti‑Xa levels with standard low-molecular-weight heparin (LMWH) dosing.
In our 200‑kg ICU patient, we implemented a fully individualized strategy using:
- weight‑based enoxaparin dosing
- twice‑daily administration
- serial anti‑Xa monitoring
- additional ROTEM analysis for anticoagulation interpretation
- dynamic dose adjustment to maintain intermediate‑intensity antithrombotic prophylaxis
The result: effective VTE prevention with no bleeding events, demonstrating the value of personalized anticoagulation in this high‑risk population.
Key insight:
An initial enoxaparin dose of 0.3 mg/kg SC BID, followed by anti‑Xa–guided adjustment, may offer a rational and safer approach for ICU patients with extreme obesity.”
Title: Optimizing prophylactic low-molecular-weight heparin anticoagulation in a 200-kg ICU patient: a case report
Authors: Piotr Filip Czempik, Dariusz Bednarski
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 15, 2026, 01:37Lesley Van Wyk: Exploring Sickle Cell Disease – The HbS Story
-
Sep 15, 2026, 01:31Luca Seffin: To the Science, the People, and the Journey – Thank You SR-Tiget
-
Sep 14, 2026, 23:49Heghine Khachatryan: New evidance – Antiphospholipid Antibodies and Ischemic Stroke
-
Sep 14, 2026, 23:42Eman M. Elsabbagh: Successful HCT Does Not End at Engraftment
-
Sep 14, 2026, 23:31Antonis Kattamis: Proud to Be Part of this Endeavour and Senior Author of the Pivotal Trial
-
Sep 14, 2026, 23:23Farjah Algahtani: Stroke Incidence and Risk Factors in Saudi Patients with Sickle Cell Disease
-
Sep 14, 2026, 20:53YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
-
Sep 14, 2026, 20:52Andres Alberto Mercado Pompa: External Validation of Prognostic Risk Scores in Cerebral Venous Thrombosis
-
Sep 14, 2026, 20:50Balaji Kirushnan: Advancing Regional Citrate Anticoagulation in CRRT – From Experience to Implementation